Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2020), Nature Medicine

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2020), Nature Medicine

Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule

Rollier CS. et al, (2020), Scientific Reports, 10

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2020), The Lancet

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478

Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells.

Bowyer G. et al, (2020), The Journal of experimental medicine, 217

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826

Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency.

Gilchrist JJ. et al, (2020), BMC medicine, 18

The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans.

Auckland K. et al, (2020), Scientific reports, 10

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.

Cappuccini F. et al, (2020), Journal for immunotherapy of cancer, 8

Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice.

Bliss CM. et al, (2020), Molecular therapy. Methods & clinical development, 16, 108 - 125

Estimating the burden of iron deficiency among African children.

Muriuki JM. et al, (2020), BMC medicine, 18

Vaccine innovations for emerging infectious diseases-a symposium report.

Cable J. et al, (2020), Annals of the New York Academy of Sciences, 1462, 14 - 26

Identification of antigens presented by MHC for vaccines against tuberculosis.

Bettencourt P. et al, (2020), NPJ Vaccines, 5

Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters.

Miyazaki S. et al, (2020), Frontiers in Cellular and Infection Microbiology, 10

The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection.

Du Y. et al, (2020), Frontiers in Immunology, 11

Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats

Stedman A. et al, (2019), npj Vaccines, 4

Identification of novel mycobacterial antigens presented by MHC-I and -II by immunopeptidomics for vaccines against tuberculosis

Bettencourt P. et al, (2019), EUROPEAN JOURNAL OF IMMUNOLOGY, 49, 1691 - 1691

The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia.

Muriuki JM. et al, (2019), Science advances, 5

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?